I am a
Home I AM A Search Login

Papers of the Week

Papers: 22 Jun 2024 - 28 Jun 2024

2024 Jun 20

J Oral Biosci


Botulinum toxin type A is a potential therapeutic drug for chronic orofacial pain.


Kim YM, Son JY, Ahn DK


Botulinum toxin type A (BTX-A), produced by the gram-positive anaerobic bacterium Clostridium botulinum, acts by cleaving synaptosome-associated protein-25 (SNAP-25), an essential component of the presynaptic neuronal membrane that is necessary for fusion with the membrane proteins of neurotransmitter-containing vesicles. Recent studies have highlighted the efficacy of BTX-A in treating chronic pain conditions, including lower back pain, chronic neck pain, neuropathic pain, and trigeminal neuralgia, particularly when patients are unresponsive to traditional painkillers. This review focuses on the analgesic effects of BTX-A in various chronic pain conditions, with a particular emphasis on the orofacial region.